Gyanu lamichhane biography sampler

  • Gyanu Lamichhane's 129 research works with 4709 citations, including: 643.
  • Gyanu Lamichhane: Writing – review & editing, Writing – original draft.
  • It is hoped that DNA from clinical samples in MAC patients could be used Gyanu Lamichhane, Johns Hopkins University School of Medicine.

    • •

    Open Access

    Peer-reviewed

    • Stephanie L. Davis,
    • Nicholas A. Be,
    • Gyanu Lamichhane,
    • Sridhar Nimmagadda,
    • Martin G. Pomper,
    • William R. Bishai,
    • Sanjay K. Jain
    • Stephanie L. Davis, 
    • Nicholas A. Be, 
    • Gyanu Lamichhane, 
    • Sridhar Nimmagadda, 
    • Martin G. Pomper, 
    • William R. Bishai, 
    • Sanjay K. Jain

    x

    Figures

    Abstract

    Background

    Bacteria can be selectively imaged in experimentally-infected animals using exogenously administered 1-(2′deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-[125I]-iodouracil ([125I]-FIAU), a nucleoside analog substrate for bacterial thymidine kinase (TK). Our goal was to use this reporter and develop non-invasive methods to detect and localize Mycobacterium tuberculosis.

    Methodology/Principal Findings

    We engineered a M. tuberculosis strain with chromosomally integrated bacterial TK under the control of hsp60 - a strong constitutive mycobacterial promoter. [125I]FIAU uptake, antimic

    •

    ABSTRACT

    The clinical importance of Mycobacterium abscessus (MABS) pulmonary disease has been increasing. However, there is still a lack of information about MIC distribution patterns and changes in clinical practice settings. The MIC results of rapidly growing mycobacteria isolated from 92 patients with nontuberculous mycobacterial pulmonary disease diagnosed from May 2019 to March 2021 were retrospectively analyzed. Most of the patients (86 patients; 93.5%) were infected with MABS; 46 with Mycobacterium abscessus subsp. abscessus (Mab), and 40 with Mycobacterium abscessus subsp. massiliense (Mma). Significant differences in susceptibility to clarithromycin (15.2% versus 80.0%, P < 0.001) and azithromycin (8.7% versus 62.5%, P < 0.001) were observed between Mab and Mma. Most isolates were susceptible to amikacin (80; 93.0%), and over half were susceptible to linezolid (48; 55.8%). Only one-quarter of isolates (22, 25.6%) were susceptible to imipenem, while more

    •

    19 May 2010

    An Interview with Bill R. Jacobs, Jr., Ph.D

    Professor of Microbiology and Immunology and of Molecular Genetics, Albert Einstein College of Medicine. This video was recorded on November 13, 2009 at Johns Hopkins University. Dr. Bill Jacobs Jacobs moved to Albert Einstein College of Medicine in 1985 to become a postdoc with Barry Bloom, who...

    18 May 2010

    This Week in TB R&D – 19 May 2010

    Global tuberculosis drug development pipeline: the need and the reality by Zhenkun Ma, Christian Lienhardt, Helen McIlleron, Andrew J Nunn, Xiexiu Wang Today, The Lancet published a series of articles on tuberculosis, which highlights the continued devastating global impact of this disease, the...

    17 May 2010

    Patent pool starts to attract interest

    This post originally appeared on SciDev.net The patent pool may boost research into neglected diseases, such as guinea worm infection. CDC PHIL (8224) by Linda Nordling 10 May 2010 [CAPE TOWN] An industry-led ‘patent

  • gyanu lamichhane biography sampler